In addition, it has also been shown that the ratio of MDSCs to CD39+CD8+ T cells could serve as a potential biomarker to predict the blocking effect of immune checkpoint inhibitors in patients with NSCLC (67, 85). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.